OneDigital Investment Advisors LLC Lowers Holdings in Bristol Myers Squibb Company $BMY

OneDigital Investment Advisors LLC lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.1% in the second quarter, HoldingsChannel reports. The fund owned 102,842 shares of the biopharmaceutical company’s stock after selling 7,872 shares during the quarter. OneDigital Investment Advisors LLC’s holdings in Bristol Myers Squibb were worth $5,926,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $25,000. Physician Wealth Advisors Inc. grew its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 202 shares during the period. Bayban purchased a new position in shares of Bristol Myers Squibb in the 4th quarter worth $31,000. Finally, EQ Wealth Advisors LLC purchased a new stake in Bristol Myers Squibb during the fourth quarter valued at about $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Stock Up 1.4%

Shares of NYSE BMY opened at $64.71 on Tuesday. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $68.10. The stock’s 50-day simple moving average is $59.75 and its 200-day simple moving average is $59.06. The firm has a market cap of $132.18 billion, a price-to-earnings ratio of 14.25, a PEG ratio of 0.17 and a beta of 0.22.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, equities analysts anticipate that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.9%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on BMY. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Roth Capital initiated coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target for the company. Guggenheim reissued a “buy” rating and issued a $75.00 price objective (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Raymond James Financial started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Finally, Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price on the stock in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Moderate Buy” and a consensus target price of $66.06.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.